Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population

Pain Physician

Volumn 13, Issue 1, 2010, Pages 71-78

  West, Robert ^a   Pesce, Amadeo ^a   West, Cameron ^a   Crews, Bridgit ^a   Mikel, Charles ^a   Almazan, Perla ^a   Rosenthal, Murray ^a   Latyshev, Sergey ^a  

^a Millennium Laboratories Research Institute   (United States)

Author keywords

7 aminoclonazepam; Clonazepam; Immunoassay; LC MS MS; Pain management; Patient compliance

Indexed keywords

ALPRAZOLAM; AMANTADINE; AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE; ATOMOXETINE; BENZOCAINE; BENZOYLECGONINE; BUPIVACAINE; BUPRENORPHINE; BUTALBITAL; CARBAMAZEPINE; CARISOPRODOL; CHLORDIAZEPOXIDE; CHLORPHENIRAMINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; KETAMINE; LAMOTRIGINE; LIDOCAINE; LORAZEPAM; LOXAPINE; MECLOZINE; MEPROBAMATE; MESORIDAZINE; PETHIDINE; PHENAZONE; UNINDEXED DRUG;

ARTICLE; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOASSAY; KIDNEY CONCENTRATING CAPACITY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PAIN; PAIN ASSESSMENT; PATIENT COMPLIANCE; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; CLINICAL LABORATORY TECHNIQUES; CLONAZEPAM; COHORT STUDIES; CROSS REACTIONS; FALSE POSITIVE REACTIONS; FORENSIC TOXICOLOGY; GABA MODULATORS; HUMANS; IMMUNOASSAY; MASS SPECTROMETRY; MEDICATION ADHERENCE; PAIN; PREDICTIVE VALUE OF TESTS; REFERENCE STANDARDS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; URINALYSIS;

EID: 76149121495     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Manchikanti L, Damron KS, McManus C, Barnhill R. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: a prospective observational study. Pain Physician 2004; 7: 431-437.
2. Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility. Pain Physician. 2008; 11:S155-S180.
3. Manchikanti L, Manchukonda R, Pampati V, Damron KS. Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short acting (hydrocodone) or long acting (methadone) opioids. Pain Physician 2005; 8:257-261.
4. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, Patel S, Manchikanti L. Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) guidelines. Pain Physician 2008; 11:S5-S62.
5. Manchikanti L, Singh A. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008; 11:S63-S88.
6. Trescot AM, Datta, S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11:S133-S153.
7. Most Commonly Prescribed Drugs. Blue Cross Blue Shield of Texas 2009. www.bcbstx.com/pdf/druglist.pdf
8. Manchikanti KN, Manchikanti L, Damron KS, Pampati V, Fellows B. Increasing deaths from opioid analgesics in the United States: An evaluation in an interventional pain management practice. J Opioid Manage 2008; 4:271-283.
9. Manchikanti L, Manchikanti KN, Pampati V, Cash, KA. Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non-cancer pain. Pain Physician 2009; 12:259-267.
10. Drugs.com Klonopin. www.drugs.com/pdr/klonopin.html. Accessed 1/4/2010.
11. Charney DS, Mihic SJ, Harris RA. Hypnotics and sedatives. Ch. 16. In: Brunton LL, Lazo JS, & Parker KL eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics 11th Edition. Mc-Graw Hill, New York 2006. p. 412.
12. Fraser AD. Psychotropic agents: the benzodiazepines. In Shaw LM, Kwong TC, Rosano TG, Orsolak PJ, Wolf BA, & Magnani B (eds) The Clinical Toxicology Laboratory. Contemporary Practice Of Poisoning Evaluation. 2001. AACC Press. Washington, DC.
13. Beck O, Lafolie P, Hjemdahl P, Borg S, Odelius G, Wirbing P. Detection of benzodiazepine intake in therapeutic doses by immunoanalysis of urine: Two techniques evaluated and modified for improved performance. Clin Chem 1992; 38:271-275.
14. Meatherall R. Optimal enzymatic hydrolysis of urinary benzodiazepine conjugates. J Anal Toxicol 1994; 18:382-384.
15. Fraser AD, Meatherall R. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: Effect of lowering the screening and GC-MS cut-off values. J Anal Toxicol 1996; 20:217-223.
16. Meatherall R, Fraser AD. Comparison of four immunoassays for the detection of lorazepam in urine. Ther Drug Monit 1998; 20:673-675.
17. White RN, Black ML Pain Management Testing Reference. AACC Press 2008. Washington, DC.
18. Mikel C, Almazan P, West R, Pesce A., West C, Latyshev S, Crews B. LC-MS/MS extends the range of drug analysis in pain patients. Ther Drug Monit 2009; 31:746-748.
19. Microgenics Product package inserts Microgenics Fremont CA. DAU DRI Benzodiazepine Assay.
20. Moore CM, Coulter C, Crompton K. Immunalysis Corp., Zumwalt, M., Agilent Technologies Inc. Determination of benzodiazepines in oral fluid using lc/ms/ms. Agilent application. www.chem.agilent.com/Library/applications/5989-7074EN.pdf
21. Target Compound Identification And Quantitation Procedure. Agilent Technologies Inc., Santa Clara, CA [MSD ChemStation Data Analysis] Last Reviewed: Marc 20, 2002.
22. Fitzgerald R. Analytical Toxicology of the Benzodiazepines. Therapeutic Drug Monitoring and Toxicology 1995; 16:169-186.
23. Valentine J, Middleton R, Sparks C. Identification of urinary benzodiazepines and their metabolites: comparison of automated hplc and gc-ms after immunoassay screening of clinical specimens. Journal of Analytical Toxicology 1996; 20:416-424.
24. Beck O, Linn Z, Brodin K, Borg S, Hjemdahl P. The online screening technique for urinary benzodiazepines: Comparison with EMIT, FPIA, and GC-MS. J Anal Toxicol 1997; 21:554-557.
25. Kurisaki E, Hayashida M, Nihira M, Ohno Y, Mashiko H, Okano T, Niwa S, & Hiraiwa K. Diagnostic performance of triage for benzodiazepines: Urine analysis of the dose of therapeutic cases. Journal of Analytical Toxicology 2005; 29:539-543.
26. Cone EJ, Caplan YH, Black DL, Robert T, Moser F. Urine drug testing of chronic pain patients: Licit and illicit drug patterns. Journal of Analytical Toxicology 2008; 32:530-543.
27. Hattab EM, Goldberger BA, Johannsen LM, Kindland PW, Ticino F, Chronister CW, Bertholf RL. Modification of screening immunoassays to detect sub-threshold concentrations of cocaine, cannabinoids, and opiates in urine: Use for detecting maternal and neonatal drug exposures. Ann Clin Lab Sci 2000; 30:85-91.
28. Fraser AD, Zamecnik J. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther Drug Monit 2003; 25:723-727.
29. Manchikanti L, Boswell MV, Singh V, Derby R, Fellows B, Falco FJE, Datta S, Smith HS, Hirsch JA. Comprehensive review of neurophysiologic basis and diagnostic interventions in managing chronic spinal pain. Pain Physician 2009; 12:E71-E120.
30. Manchikanti L, Boswell MV, Singh V, Benyamin RM, Fellows B, Abdi S, Buenaventura RM, Conn A, Datta S, Derby R, Falco FJE, Erhart S, Diwan S, Hayek SM, Helm S, Parr AT, Schultz DM, Smith HS, Wolfer LR, Hirsch JA. Comprehensive evidence-based guidelines for interventional techniques in the management of chronic spinal pain. Pain Physician 2009; 12:699-802.
31. Manchikanti L, Derby R, Wolfer LR, Singh V, Datta S, Hirsch JA. Evidencebased medicine, systematic reviews, and guidelines in interventional pain management: Part 5. Diagnostic accuracy studies. Pain Physician 2009; 12:517-540.
32. Manchikanti L, Derby R, Wolfer LR, Singh V, Datta S, Hirsch JA. Evidencebased medicine, systematic reviews, and guidelines in interventional pain management: Part 7: Systematic reviews and meta-analyses of diagnostic accuracy studies. Pain Physician 2009; 12:929-963.
33. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC; STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Fam Pract 2004; 21:4-10.